Melanocortin-4 Receptor Gene Variants and Weight Change Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy

Given the melanocortin-4 receptor's (MC4R) importance in obesity, we examined associations between <i>MC4R</i> gene variants and weight following a switch to integrase inhibitor-containing antiretroviral therapy among participants in Advancing Clinical Therapeutics Globally studies. Among 529 persons with HIV (median age: 50 years, 29% non-Hispanic Black, 22% female), 62% were overweight or obese at integrase strand transfer inhibitor switch, and 62% switched to raltegravir. In adjusted linear models, three variants were associated (<i>P</i> < .05) with weight change after switch in all participants or in prespecified subgroups. These exploratory findings are consistent with the role of melanocortins in appetite and weight and suggest a neuroendocrine contribution to integrase inhibitor-related weight gain.

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2025-11-22
DOI
https://doi.org/10.1093/ofid/ofaf696
Primary Topic
Regulation of Appetite and Obesity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Melanocortin-4 Receptor Gene Variants and Weight Change Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy

Grace A. McComsey, Paul E. Sax, Kristine Mace Erlandson, David W. Haas et al.
Open Forum Infectious Diseases
Regulation of Appetite and Obesity
article

Melanocortin-4 Receptor Gene Variants and Weight Change Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy

Grace A. McComsey, Paul E. Sax, Kristine Mace Erlandson, David W. Haas, Todd Hulgan, Jordan E. Lake, Michael Leonard, Todd T. Brown, Sara Hurtado Bares, Marylyn DeRiggi Ritchie, John R. Koethe, Kunling Wu, Katherine Tassiopoulos, Yuki Bradford
article en

Abstract

Given the melanocortin-4 receptor's (MC4R) importance in obesity, we examined associations between <i>MC4R</i> gene variants and weight following a switch to integrase inhibitor-containing antiretroviral therapy among participants in Advancing Clinical Therapeutics Globally studies. Among 529 persons with HIV (median age: 50 years, 29% non-Hispanic Black, 22% female), 62% were overweight or obese at integrase strand transfer inhibitor switch, and 62% switched to raltegravir. In adjusted linear models, three variants were associated (<i>P</i> < .05) with weight change after switch in all participants or in prespecified subgroups. These exploratory findings are consistent with the role of melanocortins in appetite and weight and suggest a neuroendocrine contribution to integrase inhibitor-related weight gain.

Open Forum Infectious DiseasesVol. 12(12)
Brigham and Women's Hospital (US), Harvard University (US), Johns Hopkins University (US), Johns Hopkins Medicine (US), Case Western Reserve University (US), University of Nebraska Medical Center (US), University of Pennsylvania (US), Vanderbilt University Medical Center (US), The University of Texas Health Science Center at Houston (US), University of Colorado Denver (US)
Openalex Percentile: Top 62%
Regulation of Appetite and Obesity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.